Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

TB-500 Year-1 Outcomes From Real Users: What Reddit and Patient Reports Actually Show

By
Published Updated Last reviewed
12 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • What TB-500 is / A synthetic 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4 [1]
  • Approval / No FDA-approved product; FDA found no approved product in Canada, Australia, the UK or authorized by the European Medicines Agency [1]
  • Human studies of TB-500 / None found [1]
  • Human safety data / No human pharmacokinetic data; no toxicity or immunogenicity studies found [1]
  • Adverse-event reports / None for TB-500 in FDA's database through March 26, 2025 [1]
  • Approved dose / None [1]
  • Sport status / WADA S2.3, prohibited at all times [3]

Is there a clinical evidence base behind year-one TB-500 reports?

No. FDA searched PubMed, Embase, ClinicalTrials.gov and other sources and found no article in which TB-500 was given to a human [1]. Without that, there is no clinical evidence base for estimating response rates, satisfaction or follow-up outcomes. A claim such as "60% of users improved by week four" has no verified source behind it: nothing confirms the person, the vial, the dose or the outcome.

What FDA found

FDA evaluated TB-500 in July 2026 for wound healing, the use its nominator proposed. None of the three papers the nominator cited involved TB-500 in humans [1]. FDA also found no in-vivo animal study of TB-500 for wound healing. In an in-vitro scratch-wound test, TB-500 at 50 micrograms/mL did not induce wound closure in fibroblast cultures, while a shorter metabolite did show activity in vitro [1].

Its adverse-event database search through March 26, 2025 retrieved no TB-500 reports. Its food and supplement complaint system (January 1, 2004 to March 10, 2025) retrieved two cases about a blended TB-500 and BPC-157 product, with no safety assessment attached [1]. FDA found no published case reports [1].

A documented patient case

FDA's BPC-157 review describes a 40-year-old woman who injected a product labelled 'research purposes only' containing 5 mg BPC-157 and 5 mg TB-500 subcutaneously twice daily. Within a week she developed widespread skin hyperpigmentation and gum darkening, which recurred when she tried the product again two weeks later [2]. Because the product held two peptides, FDA said it could not tell whether either caused the reaction [2]. A single case cannot establish how often adverse effects occur, and a reaction to a blended product cannot be attributed to TB-500 alone [1][2].

The closest thing to patient outcome data

A 2021 retrospective chart review at one Florida clinic reached 16 patients by phone after intra-articular peptide injections for knee pain: 12 had received BPC-157 alone and 4 had received BPC-157 plus thymosin beta-4, with the form not specified [4]. Three of the 4 in the combination group (75%) reported significant improvement, against 11 of 12 on BPC-157 alone [4]. There was no control group, no validated measurement tool, and the results were recalled rather than recorded [4].

Studies of the full-length protein exist and do not transfer. A phase 1 study enrolled 54 healthy volunteers in its single-dose trial and 30 in its multiple-dose trial; participants received recombinant full-length thymosin beta-4 (NL005) or placebo, with mild to moderate adverse events and no dose-limiting toxicity [5]. A 72-patient dry-eye trial of thymosin beta-4 drops found neither primary endpoint significant [6]. TB-500 is a 7-amino-acid fragment of that protein, and none of this shows that TB-500 works or is safe [1].

Dose, risk and legal status

There is no approved dose and no human dosing study; the nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for subcutaneous or intramuscular injection [1]. FDA's stated concern for injectable TB-500 is immunogenicity, potentially amplified by peptide aggregation and impurities, and it found no study of TB-500 immunogenicity or aggregation and no nonclinical toxicity studies [1].

TB-500 is not on FDA's compounding bulk-substance lists [7][8][9]. FDA staff recommended against adding it; the Pharmacy Compounding Advisory Committee voted in favour on July 23, 2026, but that vote was non-binding advice [1][10]. An HHS draft policy filed October 28, 2026 names TB-500 acetate among six peptides and says HHS does not intend to take enforcement action against certain state-licensed pharmacies and physicians if its conditions are met. The draft is not an approval, does not put TB-500 on any list, and is not binding [12]. WADA names thymosin-beta4 and its derivatives, including TB-500, in S2.3 and prohibits them at all times [3][11].

How to read a TB-500 post

Three things are worth checking. Was the vial TB-500 alone or blended with BPC-157? FDA notes that research-use-only powder is sold in 2 mg to 15 mg vials, alone or blended [1]. Was the change measured or remembered? And was the product tested for identity and impurities, given that FDA found several salts and derivatives sold under the same name [1]? A post that survives all three questions is still one person's account, not evidence of effect.

Frequently asked questions

Can a Reddit post show whether TB-500 works for tendon injuries?
Not on its own. A post describes one person's experience, with no verified product identity, no measured outcome and no comparison group. The closest study data is a 2021 chart review in which 4 of 16 knee-pain patients received BPC-157 plus thymosin beta-4; 3 of those 4 reported improvement from memory, with no control group [4].
How many people have reported side effects from TB-500?
FDA's adverse-event database search through March 26, 2025 returned no TB-500 reports, and its food and supplement complaint system returned two cases about a blended TB-500 and BPC-157 product with no safety assessment [1]. FDA's BPC-157 review also describes widespread skin and gum darkening in a woman injecting a BPC-157 and TB-500 blend; FDA could not attribute it to either peptide [2].
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic 7-amino-acid fragment (residues 17 to 23, N-acetylated) of the 43-amino-acid protein thymosin beta-4, with a molecular weight of about 889 g/mol, and it is not thymosin alpha-1 [1]. Human trials of the full-length protein, including intravenous recombinant thymosin beta-4 and eye drops, do not show that TB-500 works or is safe [1].
What dose do users report taking, and is there an approved dose?
There is no approved TB-500 dose or human dosing study, so forum schedules should not be treated as tested doses. The nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for subcutaneous or intramuscular injection [1].
Is TB-500 legal, and is it banned in sport?
TB-500 is not an FDA-approved drug and is not on FDA's compounding bulk-substance lists; a July 2026 advisory committee vote in its favour was non-binding, and an October 2026 HHS enforcement-discretion policy is a non-binding draft, not an approval [1][7][10][12]. WADA names thymosin-beta4 and its derivatives, including TB-500, in S2.3 and prohibits them at all times [3][11].

References

  1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  2. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  3. World Anti-Doping Agency. World Anti-Doping Agency
  4. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
  5. Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
  6. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
  7. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  8. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  9. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA
  10. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  11. World Anti-Doping Agency. World Anti-Doping Agency
  12. U.S. Department of Health and Human Services. Draft enforcement-discretion policy for compounding with certain peptides, Federal Register document 2026-22192. Federal Register public inspection 2026-22192
Evidence overview for TB-500 Year-1 Outcomes From Real Users: What Reddit and Patient Reports Actually Show